1
|
Yu K, Chen B, Aran D, Charalel J, Yau C, Wolf DM, van 't Veer LJ, Butte AJ, Goldstein T, Sirota M. Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types. Nat Commun 2019; 10:3574. [PMID: 31395879 PMCID: PMC6687785 DOI: 10.1038/s41467-019-11415-2] [Citation(s) in RCA: 80] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2018] [Accepted: 07/10/2019] [Indexed: 01/03/2023] Open
Abstract
Cancer cell lines are a cornerstone of cancer research but previous studies have shown that not all cell lines are equal in their ability to model primary tumors. Here we present a comprehensive pan-cancer analysis utilizing transcriptomic profiles from The Cancer Genome Atlas and the Cancer Cell Line Encyclopedia to evaluate cell lines as models of primary tumors across 22 tumor types. We perform correlation analysis and gene set enrichment analysis to understand the differences between cell lines and primary tumors. Additionally, we classify cell lines into tumor subtypes in 9 tumor types. We present our pancreatic cancer results as a case study and find that the commonly used cell line MIA PaCa-2 is transcriptionally unrepresentative of primary pancreatic adenocarcinomas. Lastly, we propose a new cell line panel, the TCGA-110-CL, for pan-cancer studies. This study provides a resource to help researchers select more representative cell line models. Cell lines are used ubiquitously in cancer research but how well they represent the tumor type they were derived from is variable. Here, the authors compare transcriptomic profiles of 22 tumor types and cell lines and propose a new comprehensive cell line panel for pan-cancer studies.
Collapse
Affiliation(s)
- K Yu
- Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, 94158, CA, USA.,Department of Pediatrics, University of California, San Francisco, San Francisco, 94143, CA, USA
| | - B Chen
- Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, 49503, MI, USA.,Department of Pharmacology and Toxicology, College of Human Medicine, Michigan State University, Grand Rapids, 49503, MI, USA
| | - D Aran
- Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, 94158, CA, USA
| | - J Charalel
- Department of Genetics, Stanford University, Stanford, 94305, CA, USA
| | - C Yau
- Buck Institute for Research on Aging, Novato, 94945, CA, USA.,Department of Surgery, University of California, San Francisco, San Francisco, 94143, CA, USA
| | - D M Wolf
- Department of Surgery, University of California, San Francisco, San Francisco, 94143, CA, USA
| | - L J van 't Veer
- Department of Laboratory Medicine, University of California, San Francisco, San Francisco, 94143, CA, USA
| | - A J Butte
- Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, 94158, CA, USA.,Department of Pediatrics, University of California, San Francisco, San Francisco, 94143, CA, USA
| | - T Goldstein
- Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, 94158, CA, USA
| | - M Sirota
- Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, 94158, CA, USA. .,Department of Pediatrics, University of California, San Francisco, San Francisco, 94143, CA, USA.
| |
Collapse
|
2
|
Wolf DM, Yau C, Wulfkuhle J, Petricoin E, Campbell M, Brown-Swigart L, Hirst G, Asare S, Zhu Z, Lee EP, Delson A, Pohlmann P, Hylton N, Liu MC, Symmans F, DeMichele A, Yee D, Berry D, Esserman L, van 't Veer L. Abstract P3-10-02: Identifying breast cancer molecular phenotypes to predict response in a modern treatment landscape: Lessons from ˜1000 patients across 10 arms of the I-SPY 2 TRIAL. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-10-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The explosion in new treatment options targeting immune checkpoints, HER signaling, DNA repair deficiency, AKT, and other pathways calls for updated breast cancer subtypes beyond HR and HER2 status to predict which patients will respond to which treatments. Here we leverage the I-SPY 2 TRIAL biomarker program over the past 8 years across 10 treatment arms to elucidate a minimal set of biomarkers that may improve response prediction in a modern treatment context, and to investigate which new patient phenotypes are identified by these response-predictive biomarkers.
Methods: 986 patients were considered in this analysis. Treatments included paclitaxel alone (or with trastuzumab (H) in HER2+) or combined with investigational agents: veliparib/carboplatin (VC); neratinib; MK2206; ganitumab; ganetespib; AMG386; TDM1/pertuzumab (P); H/P; and pembrolizumab (Pembro). 24 prospectively defined, mechanism-of-action and pathway-based expression and phospho-protein signatures/biomarkers assayed from pre-treatment biopsies were previously found to be predictive in a particular agent/arm in pre-specified analysis. Here we evaluate these biomarkers in all patients. We assessed association between each biomarker and response in the population as a whole and within each arm and HR/HER2 subtype using a logistic model. To identify optimal dichotomizing thresholds for select biomarkers, 2-fold cross-validation was repeated 500 times. Our analysis is exploratory and does not adjust for multiplicities.
Results: Our initial set of 24 predictive biomarkers reflects DNA repair deficiency (n=2), immune activation (n=7), ER signaling (n=2), HER2 signaling (n=4), proliferation (n=2), phospho-activation of AKT/mTOR (n=2), and ANG/TIE2 (n=1) pathways, among others. Biomarkers reflecting similar biology are correlated and cluster together. We make use of this correlation structure to reduce the dimensionality of the biomarker set to five predictive signals: proliferation, DNA repair deficiency (DRD), immune-engaged (Immune+), luminal/ER (lum), and HER2-activated. These biomarkers, when dichotomized, identify patient groups with differential predicted sensitivities to I-SPY 2 agents and are present at different proportions within receptor subtypes. For instance, in the HER2- subset, Immune+/DRD+ patients are predicted sensitive to both VC and Pembro, and account for 39% of TN, but only 12% of HR+HER2-. On the other end of the spectrum, only 17% of TN are Immune-/DRD-, compared to the majority (56%) of HR+HER2-. There are also subsets of patients positive for only one marker. For the HER2+ subset, 67% are HER2-activated+, and 25% lum+; of these HER2-activated+ patients are more likely to be Immune+ (44%), vs 23% in lum+. HER2-activated+/Immune+ patients have higher predicted sensitivity to HER2-targeted agents than lum+ or Immune- patients.
In all, these molecular phenotypes predict sensitivity to one or more I-SPY 2 investigational agents for 75% of the ˜ 1000 patients.
Conclusion: Molecular phenotypes reflecting proliferation, immune engagement, HER2-activation, luminal/ER-signaling, and DNA repair deficiency may provide a roadmap to guide treatment prioritization for emerging therapeutics.
Citation Format: Wolf DM, Yau C, Wulfkuhle J, Petricoin E, Campbell M, Brown-Swigart L, Hirst G, Asare S, Zhu Z, Lee EP, Delson A, Pohlmann P, I-SPY 2 TRIAL Consortium, Hylton N, Liu MC, Symmans F, DeMichele A, Yee D, Berry D, Esserman L, van 't Veer L. Identifying breast cancer molecular phenotypes to predict response in a modern treatment landscape: Lessons from ˜1000 patients across 10 arms of the I-SPY 2 TRIAL [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-10-02.
Collapse
Affiliation(s)
- DM Wolf
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - C Yau
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - J Wulfkuhle
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - E Petricoin
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - M Campbell
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - L Brown-Swigart
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - G Hirst
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - S Asare
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - Z Zhu
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - EP Lee
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - A Delson
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - P Pohlmann
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - N Hylton
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - MC Liu
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - F Symmans
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - A DeMichele
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - D Yee
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - D Berry
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - L Esserman
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | - L van 't Veer
- University of California, San Francisco; George Mason University, Fairfax; QuantumLeap Healthcare Collaborative, San Francisco; University of Texas, MD Anderson, Houston; University of Pennsylvania, Philadelphia; University of Minnesota, Minneapolis; Berry Consultants, LLC, Austin; Mayo Clinic, Rochester; Georgetown University, Washington, DC
| | | |
Collapse
|
3
|
Gallagher RI, Yau C, Wolf DM, Dong T, Hirst G, Brown-Swigart L, Buxton M, DeMichele A, van't Veer L, Yee D, Paoloni M, Esserman L, Berry D, Park J, Petricoin EF, Wulfkuhle JD. Abstract P3-05-02: Quantitative ERα measurements in TNBC from the I-SPY 2 TRIAL correlate with HER2-EGFR co-activation and heterodimerization. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-05-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: We have previously described that TNBC patients whose tumors have both HER2 Y1248 phosphorylation (pHER2) “high” and phospho-EGFR Y1173 (pEGFR) “high” have increased response (pCR) to neratinib in the I-SPY2 TRIAL. We hypothesize that the paradoxical finding of a response prediction signature comprised of HER2 activation in a HER2 IHC/FISH-negative population means there must be a ligand-driven biochemical event responsible for the HER2 phosphorylation because HER2 mutations were also not found to be significant. Exploratory analysis of additional cellular signaling events and protein expression levels in pre-treatment, LCM-purified tumor epithelium by reverse phase protein microarray (RPPA) included semi-quantitative measurement of total levels of estrogen receptor alpha (ERα), which has been previously shown to be able to act as a membrane non-genomic signaling molecule through direct interaction with various tyrosine kinases including EGFR and HER2. Since ERα has been previously shown to act as a ligand and co-stimulate (activate) HER2 and EGFR when present at low levels, we investigated whether or not RPPA-measured ERα levels in the TNBC cohort analyzed to date were higher in tumors with both pHER2 “high” and pEGFR “high” levels and thus provide evidence explaining how HER2-EGFR activation is occurring in TNBC.
Methods: Using RPPA analysis, we measured 118 analytes in lysates of LCM tumor epithelium obtained from the pre-treatment biopsy samples of 86 TNBC (Allred=0) patients in the I-SPY2 TRIAL analyzed to date. Cutpoints for pEGFR and pHER2 were determined previously by ROC analysis for pCR correlation in the neratinib treated TNBC population, and used here to dichotomize the pHER2 and pEGFR data in the larger TNBC population. Wilcoxon Rank Sum testing was performed using the continuous variable total ERα data and compared the TNBC that were both pHER2 and pEGFR “high” (N=39) to the rest of the TNBC population (N=47). Total ERα values were then divided into “high” and “low” groups based on the TNBC population median value in order to determine frequency/percentages within each class. Our study is exploratory with no claims for generalizability of the data, and calculations are descriptive (e.g. p-values are measures of distance with no inferential content).
Results: Total ERα values were obtained in 84/86 TNBC tumors analyzed. Total levels of ERα were higher (p< 0.006) in TNBC tumors with pHER2 and pEGFR “high” levels. 68% (26/38) of tumors in the pHER2 and pEGFR “high” group had ERα levels above the population median compared to 35% (16/46) in the rest of the TNBC population.
Conclusion: Our exploratory analysis reveals that ERα levels are significantly higher in TNBC with pHER2 and pEGFR activation and may be behaving as a direct signaling ligand in TNBC and driving HER2-EGFR signaling. This ERα-pHER2/pEGFR association was missed by current ER and HER2 clinical laboratory testing techniques, and if validated in larger independent study sets could suggest that utilization of new protein-based techniques defining ER more quantitatively could be helpful to understand tumor biology and therapeutic response prediction, especially in the context of TNBC that are ostensibly ER negative.
Citation Format: Gallagher RI, Yau C, Wolf DM, Dong T, Hirst G, Brown-Swigart L, ISPY-2 TRIAL Investigators, Buxton M, DeMichele A, van't Veer L, Yee D, Paoloni M, Esserman L, Berry D, Park J, Petricoin EF, Wulfkuhle JD. Quantitative ERα measurements in TNBC from the I-SPY 2 TRIAL correlate with HER2-EGFR co-activation and heterodimerization [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-05-02.
Collapse
Affiliation(s)
- RI Gallagher
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - C Yau
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - DM Wolf
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - T Dong
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - G Hirst
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - L Brown-Swigart
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - M Buxton
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - A DeMichele
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - L van't Veer
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - D Yee
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - M Paoloni
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - L Esserman
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - D Berry
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - J Park
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - EF Petricoin
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | - JD Wulfkuhle
- George Mason University, Manassas, VA; University of California San Francisco School of Medicine, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Minnesota School of Medicine; Berry Consultants, LLC
| | | |
Collapse
|
4
|
Davies S, Dai D, Wolf DM, Leslie KK. Immunomodulatory and Transcriptional Effects of Progesterone Through Progesterone A and B Receptors in Hec50co Poorly Differentiated Endometrial Cancer Cells. ACTA ACUST UNITED AC 2016; 11:494-9. [PMID: 15458748 DOI: 10.1016/j.jsgi.2004.04.003] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
OBJECTIVE Derivatives of progesterone, progestins, are used to treat endometrial cancer; however, the pathways activated by the hormone have not been fully investigated. Progesterone acts through two receptor isoforms, progesterone receptors A and B (PRA and PRB), transcription factors that control the expression of downstream genes leading to endometrial differentiation. The purpose of this study was to perform an expression analysis to identify the mechanisms underlying progesterone's growth suppressive and immunomodulatory effects in endometrial cancer. METHODS To study the molecular effects of progesterone, PRs were introduced into Hec50co cells. Expression array analyses followed by confirmatory semiquantitive reverse-transcriptase polymerase chain reaction (RT-PCR) experiments were performed. RESULTS Expression analysis demonstrated a significant effect of progesterone after 12 hours of treatment on a number of genes, including cell signaling, DNA remodeling, apoptotic, tumor-suppressor, and transcription factors. Of particular interest was the consistent modulation of cytokines, which generally predicted for a powerful anti-inflammatory effect of progesterone through PR. Specifically, pro-inflammatory genes such as TNFalpha, IL-1beta, and MCP-1/MCAF-1 were down-regulated and anti-inflammatory genes such as TRAP1 and SMAD4 were induced. CONCLUSION We have discovered that progesterone has a modulatory effect on inflammation and many other important cellular functions. These effects likely underlie the inhibitory effects of progesterone on tumor growth and invasion.
Collapse
Affiliation(s)
- Suzy Davies
- Reproductive Molecular Biology Laboratory, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87131, USA
| | | | | | | |
Collapse
|
5
|
Wolf DM, Keck S, Yau C, Livasy C, Mori M, Baehner R, van 't Veer L, Esserman L, Rugo H. Abstract P1-02-06: Assigning luminal A versus luminal B subtype using the Ki67 index in patients with hormone receptor positive (HR+) breast cancer enrolled in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-02-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Prognostically distinct subtypes of BC defined by gene expression include luminal A, luminal B, HER2-enriched, basal-like and normal breast-like tumors. Luminal subtypes express estrogen receptor (ER)-related genes; patients with luminal B tumors have a poorer prognosis and higher proliferation compared to those with luminal A tumors. For HR+ disease, accessible and affordable surrogates for identification of luminal subtypes may aid in selecting appropriate systemic therapy and assessing eligibility to novel agent clinical trials targeted toward specific biology. Recent studies support use of Ki67 positivity by immunohistochemistry (IHC) with a cut point of 15%, along with standard receptors, as an appropriate surrogate for luminal B.
Methods: 116 I-SPY 1 TRIAL patients with intrinsic subtype assignments had Ki-67 IHC-stained pre-treatment whole tissue sections available for digital image quantification. The percentage of Ki67-positive nuclei was quantified using the Aperio Nuclear V9 (cell quantification) algorithm. Intrinsic subtype was previously determined by standard methods applied to Agilent 44K gene expression data. We selected the 49 patients with HR+/HER2- tumors for this analysis. Ki67 positivity was categorized into two groups: low (<15%) and high (≥15%). Association between intrinsic subtype and Ki67 was determined using Fisher's exact method.
Results: The 49 pts with HR+/HER2- disease were classified by gene expression into intrinsic subtypes as follows: 26 (53%) luminal A, 15 (31%) luminal B, 2 (4%) HER2-enriched, 6 (12%) basal, and 0 normal. The fraction of Ki67 positive cells ranged from 0.28% to 86.8%, with a mean of 20.5%. The mean Ki67 positive fraction was 13% and 24% in LumA and LumB subgroups, respectively. Using the 15% cutoff, Ki67 was low in 25 (51%) and high in 24 (49%) cases. The majority of luminal A tumors have low Ki67 (17/26, 65%) and luminal A subtype was associated with Ki67 (p = 0.047). However, nearly a third of tumors with low Ki67 are not luminal A (8/25, 32%). High Ki67 tumors were distributed among luminal A (18%), luminal B (18%), basal (10.2%), and HER2-enriched (2%) subtypes; luminal B subtype was not associated with high Ki67 (p = 0.36) in this cohort.
Conclusion: In this high-risk population, 16% of HR+/HER2- tumors were either basal or HER2-enriched by intrinsic subtyping. Low Ki67 (<15%) was associated with luminal A; this did not exclude other subtypes. In this well characterized group, high Ki67 (≥15%) in combination with ER status did not serve as a surrogate for luminal B subtype. These results suggest that intrinsic subtype classifications reflect information beyond that captured by hormone receptor status combined with Ki67 positivity.
This research was partially supported by NIH CA31946 and CA33601.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-02-06.
Collapse
Affiliation(s)
- DM Wolf
- University of California, San Francisco; University of North Carolina, Chapel Hill; Genomic Health, Redwood City; I-SPY 1 Trial
| | - S Keck
- University of California, San Francisco; University of North Carolina, Chapel Hill; Genomic Health, Redwood City; I-SPY 1 Trial
| | - C Yau
- University of California, San Francisco; University of North Carolina, Chapel Hill; Genomic Health, Redwood City; I-SPY 1 Trial
| | - C Livasy
- University of California, San Francisco; University of North Carolina, Chapel Hill; Genomic Health, Redwood City; I-SPY 1 Trial
| | - M Mori
- University of California, San Francisco; University of North Carolina, Chapel Hill; Genomic Health, Redwood City; I-SPY 1 Trial
| | - R Baehner
- University of California, San Francisco; University of North Carolina, Chapel Hill; Genomic Health, Redwood City; I-SPY 1 Trial
| | - L van 't Veer
- University of California, San Francisco; University of North Carolina, Chapel Hill; Genomic Health, Redwood City; I-SPY 1 Trial
| | - L Esserman
- University of California, San Francisco; University of North Carolina, Chapel Hill; Genomic Health, Redwood City; I-SPY 1 Trial
| | - H Rugo
- University of California, San Francisco; University of North Carolina, Chapel Hill; Genomic Health, Redwood City; I-SPY 1 Trial
| | | |
Collapse
|
6
|
Boudreau A, Elias SG, Yau C, Wolf DM, van't Veer LJ. Abstract P4-09-02: A robust signature of long-term clinical outcome in breast cancer. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p4-09-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Multigene prognostic signatures derived from high-dimensional mRNA expression data have been proposed to forecast patient outcome and predict chemotherapy benefit more accurately than standard clinical parameters. However, many prognostic signatures fail to predict late recurrences occurring 10 or more years following initial diagnosis. Furthermore, breast cancer subtypes canonically associated with favorable biology, particularly estrogen-receptor positive disease, are characterized by a higher frequency of late recurrences. Patients identified as being at a higher risk of late recurrence might benefit from more prolonged systemic (hormonal) therapy; as such, the goal of this research has been to develop a prognostic signature that can faithfully stratify patient risk up to and beyond 10 years of follow-up.
Methods: A novel multiplexed Cox modeling approach was applied to microarray data obtained from an untreated, node-negative patient cohort with long-term follow-up (n = 141) to train the signature. The long-term prognostic signature was subsequently validated in an additional group of patients (n = 154) that were mostly node-positive (94%) and administered adjuvant chemotherapy (71%). The performance of the signature was compared to existing clinicopathological parameters and genomic signatures using Cox proportional hazards analysis. Logistic regression modeling was employed to evaluate the added benefit to discriminatory accuracy obtained by incorporating the long-term prognostic signature alongside current biomarkers to predict 10-year overall survival.
Results: The long-term signature was able to stratify patient risk with unprecedented accuracy compared to standard clinicopathological and genomic features in both the training and the validation cohorts; none of the patients predicted to have good biology (n = 47 and 38) died within 10 years in either cohort, whereas only 34% and 44% of patients predicted to have poor biology (n = 47 and 46) survived 10 years in the training and validation cohorts, respectively. Within the validation series, the signature was able to identify patients at risk of metastasis with the highest hazard ratio in comparison to other prognostic signatures (univariate hazard ratio of 14.0 [95% CI 3.2–58; p = 0.00083], adjusted hazard ratio of 5.2 [95% CI 1.2–22; p = 0.0257] when corrected for standard clinicopathological markers). Adding the long-term prognostic signature to existing prognostic biomarkers led to significantly improved classification of patients into appropriate 10-year overall survival risk categories (Net Reclassification Improvement of 25.1% in validation series at >5% risk threshold, p = 0.0123).
Conclusions: We were able to identify a 200-gene long-term signature able to stratify patient risk with superior accuracy over a relatively long follow-up period. We are currently using this algorithm to develop prognostic signatures for other cancer types, and are using similar multiplexed algorithms to develop gene signatures able to predict response to neoadjuvant therapy.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-09-02.
Collapse
Affiliation(s)
- A Boudreau
- University of California, San Francisco; Netherlands Cancer Institute
| | - SG Elias
- University of California, San Francisco; Netherlands Cancer Institute
| | - C Yau
- University of California, San Francisco; Netherlands Cancer Institute
| | - DM Wolf
- University of California, San Francisco; Netherlands Cancer Institute
| | - LJ van't Veer
- University of California, San Francisco; Netherlands Cancer Institute
| |
Collapse
|
7
|
Wolf DM, Yau C, Magbanua M, Boudreau A, Davis S, Haqq C, Park J, Esserman L, van't Veer L. Abstract P2-05-01: Gene expression changes associated with response to neoadjuvant chemotherapy are observed early in treatment: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-05-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Prior gene expression profiling studies have identified markers that are predictive of chemotherapy response using pre-treatment biopsies. However, this approach does not account for chemotherapy-induced perturbation in signaling within tumors early in treatment that may predict response to therapy with superior sensitivity to baseline signatures. We hypothesized that measuring early changes in gene expression induced by neoadjuvant chemotherapy might yield improved markers of treatment efficacy and patient outcome.
Methods: Transcriptome data from 34K probe cDNA microarrays were assembled using serial biopsies obtained from 36 I-SPY 1 TRIAL patients before treatment (T1), and 24-72 hours after beginning neoadjuvant anthracycline-based chemotherapy (T2). Outcome parameters included residual cancer burden (RCB) after therapy and recurrence free survival (RFS). Gene expression changes occurring between T1 and T2 (T2-T1) were compared between known responders (RCB 0/1) and non-responders (RCB 2/3) using a permutation test based on the t-statistic; Cox proportional hazards modeling was used to identify early response genes associated with RFS. Due to the small sample sizes, we adopted a relaxed significance threshold for outcome associations (p-value<0.005 without multiple testing correction). Pathway analyses were performed with Ingenuity IPA software.
Results: 97 genes were found to be differentially altered upon comparing early gene expression changes (T2-T1) between responders (RCB 0/1) and non-responders (RCB 2/3). Ingenuity IPA software identified cell cycle as the top enriched pathway (p = 0.0008) among these differentially altered genes, with responders showing relative up-regulation of translation regulator EIF4EBP1 and cell cycle regulators CDKN2B and SMARCB1 after treatment. Survival analysis identified changes (T2-T1) in 293 genes as significantly associated with RFS; these genes were enriched in pathways including lipid antigen presentation by CD1, cell death and drug metabolism, and notch signaling. Surprisingly, only 4 genes were associated with both RCB and RFS, likely reflecting a prognostic signal from the many non-responding patients with favorable outcomes. Intrinsic subtype assignments were 75% concordant between time points T1 and T2, with basal classifications remaining stable (13/13) and some inter-conversion among LumA, LumB, Her2, and Normal (9/23). Interestingly, a larger number of genes were associated with chemotherapy response when one considered the change in expression (T2-T1), rather than absolute expression levels at T1 (17 genes) or at T2 (87 genes). Moreover, there was negligible overlap between these three response associated gene sets (T1, T2, and T2-T1 change), indicating that early expression changes may provide information beyond signatures obtained at static time points.
Conclusion: These analyses suggest that pre-treatment, early treatment and early changes provide non-redundant information on chemotherapy responsiveness and outcome. Early expression changes might be combined with data from pre-treatment biopsies to construct early predictors of non-response, an essential component within an adaptive treatment framework.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-05-01.
Collapse
Affiliation(s)
- DM Wolf
- University of California, San Francisco, CA; I-SPY 1 TRIAL Institutions
| | - C Yau
- University of California, San Francisco, CA; I-SPY 1 TRIAL Institutions
| | - M Magbanua
- University of California, San Francisco, CA; I-SPY 1 TRIAL Institutions
| | - A Boudreau
- University of California, San Francisco, CA; I-SPY 1 TRIAL Institutions
| | - S Davis
- University of California, San Francisco, CA; I-SPY 1 TRIAL Institutions
| | - C Haqq
- University of California, San Francisco, CA; I-SPY 1 TRIAL Institutions
| | - J Park
- University of California, San Francisco, CA; I-SPY 1 TRIAL Institutions
| | - L Esserman
- University of California, San Francisco, CA; I-SPY 1 TRIAL Institutions
| | - L van't Veer
- University of California, San Francisco, CA; I-SPY 1 TRIAL Institutions
| | | |
Collapse
|
8
|
Wolf DM, Yau C, Benz S, Vaske C, Stuart J, Roy R, Olshen A, Boudreau A, Haussler D, Gray J, Spellman P, Davis S, Hylton N, Van Veer L, Esserman L. P1-06-09: Patient-Specific Integrative Pathway Analysis Using PARADIGM Identifies Key Activities in I-SPY 1 Breast Cancer Patients (CALGB 150007/150012; ACRIN 6657). Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p1-06-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A major challenge in interpreting high-throughput multianalyte genomic data sets such as those produced by the ISPY clinical trials is data integration and interpretation within the context of biologically relevant pathways. To address this need, the data analysis tool PARADIGM (PAthway Recognition Algorithm using Data Integration on Genomic Models) was developed to infer the activities of genetic pathways by integrating any number of functional genomic data sets for a given patient sample into a pathway activity profile.
Methods: We used PARADIGM to integrate gene expression (Agilent 44K) and DNA copy number data (AFFY 22K and 330K MIP) from 133 ISPY-1 patients into pathway component activity levels for approximately 1400 curated signal transduction, transcriptional and metabolic pathways superimposed onto a single non-redundant ‘SuperPathway'. These pathway activities then become the substrate for statistical analyses to identify pathways characterizing different breast cancer subtypes, as well as those associated with recurrence and response to neoadjuvant chemotherapy within breast cancer subgroups. To identify subtype-specific pathway activities, we used ANOVA for initial feature filtering followed by Tukey analysis with Benjamini Hochberg multiple testing correction. For other binary outcome comparisons we used Mann-Whitney (2-sample Wilcoxon) analysis. PARADIGM results were corroborated with pathway enrichment analysis and filtered for significance.
Results: In agreement with breast cancer cell line and other prior studies, basal-like and triple negative cancers are dominated by upregulation of the FOXM1 and MYC/Max subnetworks and downregulation of the FOXA1/ER signal transduction pathway, the converse of the activity pattern seen in luminal breast cancers. These and other subtype associations pass stringent multiple testing corrected significance tests. Though an association study of recurrence over the entire patient cohort mostly yields pathways characteristic of basal-like tumors, alternative pathway associations emerge when subtypes are analyzed individually for outcome and significance tests are relaxed to include features that pass un-corrected Wilcoxon significance tests and also generate highly significant pathway enrichment scores. Subtype-specific drivers of recurrence and chemo-resistance supported by this level of evidence include ALK1/2 (TGFB-BMP) and p53 effector signaling for basals and Syndecan-1 and c-MYC for luminals. Chemo-sensitivity pathways, assessed by association with pCR and RCB1, appear to be subtype-specific as well, with HDAC class 1 signaling, LRP6-Wnt, and IRE1alpha chaperones dominating basal-like cancers and c-MYB activity dominating Her2+ cancers, whereas chemo-sensitivity of HR+Her2- cancers though rare appears to be driven by the DNA damage axis (BRCA/BARD1). Conclusion: These and other similar analyses suggest that patients with TN or basal-like disease might benefit from the addition of ALK1 pathway inhibitors to treatment, whereas high risk HR+ patients might benefit from Syndecan-1 inhibitors. C-MYC/MAX inhibitors might benefit all high risk patients.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-06-09.
Collapse
Affiliation(s)
- DM Wolf
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - C Yau
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - S Benz
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - C Vaske
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - J Stuart
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - R Roy
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - A Olshen
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - A Boudreau
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - D Haussler
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - J Gray
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - P Spellman
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - S Davis
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - N Hylton
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - L Van Veer
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| | - L Esserman
- 1University of California, San Francisco; University of California, Santa Cruz; Oregon Health & Science University; I-SPY 1 Trial Investigators
| |
Collapse
|
9
|
Boudreau A, Yau C, Petrillo L, Stemke-Hale K, Mills GB, Gray JW, Wolf DM, van ‘t Veer LJ. P5-01-05: Activating Mutations in PIK3CA or AKT1 in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657). Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-01-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Mutations in the catalytic domain of phosphatidylinositol 3-kinase (PIK3CA) are among the most frequently observed activating mutations in breast cancer. We used the I SPY 1 TRIAL, a group of biologically and clinically high risk patients molecularly profiled and treated with neoadjuvant chemotherapy, to determine the frequency of mutations and their relationship to pathologic complete response (pCR) and outcomes, within the entire cohort and within subtypes defined by growth and hormone receptor (HR) expression.
Methods: Patients enrolled in the I-SPY 1 TRIAL had a tumor size ≥3.0cm and were administered a doxorubicin-containing regimen, followed by a taxane, prior to surgery. Sequenom single nucleotide polymorphism (SNP) profiling was performed on breast tumor genomic DNA isolated from a subset of patients (n=152). A total of 149 SNPs covering 16 genes (including PIK3CA and AKT1/2/3) were analyzed. Mutations were tested for association with estrogen receptor (ER), progesterone receptor (PgR), and HER2 status, as well as pCR, using Fisher's exact test; associations between mutations and recurrence-free survival (RFS) were measured by log-rank tests. pCR was defined as no invasive tumor present in either the breast or axillary lymph nodes following neoadjuvant treatment.
Results: Of 149 mutations profiled in the cohort, 13 of the SNPs were observed. PIK3CA mutations were the most frequently observed in the panel (15.1%), followed by AKT1(E17K; 2.7%), CTNNB1 (D32; 1.4%), NRAS(Q61; 0.7%), and FGFR2(N549; 0.7%). Mutations in PIK3CA or AKT1 was associated with ER-positivity (p=0.0047) and PgR-positivity (p=0.044). Within receptor subtypes, the frequencies of PIK3CA/AKT1 mutations were also significantly different (HR+HER2−: 27%:(18/68); HER2+ 20% (8/40) [HR+HER2+: 26%, HR-HER2+: 14%]; HR-HER2−: 0% (0/36), p<0.0008). Unlike previous reports (Loi et al, PNAS 2010), no significant association between PIK3CA/AKT mutation status and RFS was observed when we restricted our analysis to the adjuvant endocrine treated subset of the HR+HER2− patients (n=49; log rank p = 0.369). In contrast, and similar to cell line reports (Junttila et al, Cancer Cell 2009), PIK3CA mutations appears to associate with worse RFS within the small subset of trastuzumab treated HER2+ patients (n=22, 13 HR-HER2+, 9 HR+HER2−; log rank p=0.001), suggesting mutations may influence response. Similar analyses of a larger cohort are planned to confirm these observations.
Conclusions: Within the I-SPY 1 TRIAL cohort, PIK3CA and AKT1 mutations are much more frequent in the HR+ and HER2 subsets but are not predictive of response to therapy or outcome except potentially within the HER2+ subset. The potential link observed between activating PIK3CA/AKT mutations and trastuzumab resistance merits further investigation, as it may provide a clinical rationale for testing PIK3CA mutation status in HER2+ patients and investigating combinational therapies targeting this pathway, particularly in the HER2+HR+ subset which have an elevated risk for recurrence despite pCR and trastuzumab therapy.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-01-05.
Collapse
Affiliation(s)
- A Boudreau
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - C Yau
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - L Petrillo
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - K Stemke-Hale
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - GB Mills
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - JW Gray
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - DM Wolf
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - LJ van ‘t Veer
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| |
Collapse
|
10
|
Wolf DM, Rokicka-Milewska R, Lopaciuk S, Skotnicki AB, Klukowska A, Laguna P, Windyga J, Kotitschke R, Struff WG. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate HaemoctinR SDH in previously treated patients with severe haemophilia A. Haemophilia 2004; 10:438-48. [PMID: 15357768 DOI: 10.1111/j.1365-2516.2004.00947.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Clinical efficacy, safety and pharmacokinetic properties of the high-purity double-virus inactivated plasma-derived factor VIII concentrate Haemoctin SDH (pdFVIII) were evaluated in three prospective open-label uncontrolled studies in previously treated patients (PTPs) with severe haemophilia A. The pharmacokinetic properties assessed at baseline and after 3 months of treatment are in accurate accordance with published data and remain unchanged over time (study A, n = 12). Mean terminal elimination half-life was 11.8 and 11.9 h, mean incremental recovery (IU dL(-1)/IU kg(-1)) was 2.3 and 2.0, respectively. Long-term efficacy and safety, in particular the potential immunogenicity, were investigated in a total of 53 PTPs (studies A and B) treated prophylactically and on-demand, as required. PdFVIII has shown to be effective in preventing and controlling bleeding episodes; 23.5% of patients were free of bleeding events. A total of 177 haemorrhages occurred with 74.0% resolving after a single infusion, 87.6% within two infusions. 98.3% of responses reported on haemorrhages were rated as 'excellent' or 'good'. Moreover, 'excellent' haemostatic efficacy has been demonstrated in 10 surgical procedures including general and severe orthopaedic interventions (study C). No complication occurred in any surgery. Few adverse events were reported, one patient developed a high-titre FVIII inhibitor without clinical relevance. In all three studies, over 6 million units were administered in nearly 4300 infusions, approximately 94% units or infusions were given for prophylaxis and only 6% for treatment on-demand. In conclusion, pdFVIII has shown to be effective, safe and well tolerated in long-term prophylaxis and treatment on-demand as well as after minor and major surgical procedures.
Collapse
Affiliation(s)
- D M Wolf
- Biotest Pharma GmbH, Dreieich, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Coletta RD, Christensen K, Reichenberger KJ, Lamb J, Micomonaco D, Huang L, Wolf DM, Müller-Tidow C, Golub TR, Kawakami K, Ford HL. The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci U S A 2004; 101:6478-83. [PMID: 15123840 PMCID: PMC404070 DOI: 10.1073/pnas.0401139101] [Citation(s) in RCA: 166] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Homeobox genes constitute a large family of transcription factors that are essential during normal development and are often dysregulated in cancer. However, the molecular mechanisms by which homeobox genes influence cancer remain largely unknown. Here we show that the tissue-restricted cyclin A1 is a transcriptional target of the Six1 homeoprotein. Both genes are expressed in the embryonic but not the terminally differentiated mammary gland, and Six1-knockout mice show a dramatic reduction of cyclin A1 in the embryonic mammary gland. In addition, both genes are reexpressed in breast cancers. Six1 overexpression increases cyclin A1 mRNA levels and activity, cell proliferation, and tumor volume, whereas Six1 down-regulation decreases cyclin A1 mRNA levels and proliferation. Overexpression of Six1 in wild-type mouse embryonic fibroblasts, but not in knockout variants lacking the cyclin A1 gene, induces cell proliferation. Furthermore, inhibition of cyclin A1 in Six1-overexpressing mammary carcinoma cells decreases proliferation. Together these results demonstrate that cyclin A1 is required for the proliferative effect of Six1. We conclude that Six1 overexpression reinstates an embryonic pathway of proliferation in breast cancer by up-regulating cyclin A1.
Collapse
Affiliation(s)
- Ricardo D Coletta
- Department of Obstetrics and Gynecology, University Colorado Health Sciences Center, Denver, CO 80262, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Gibbs RS, McDuffie RS, Kunze M, Barr JM, Wolf DM, Sze CI, Shikes R, Sherman MP. Experimental intrauterine infection with Prevotella bivia in New Zealand White rabbits. Am J Obstet Gynecol 2004; 190:1082-6. [PMID: 15118646 DOI: 10.1016/j.ajog.2003.10.700] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVE The purpose of this study was to develop a model of chronic intrauterine and fetal infection with Prevotella bivia, an anaerobe of the lower genital tract that is associated often with bacterial vaginosis. STUDY DESIGN Thirty timed pregnant New Zealand White rabbits on gestational day 21 were inoculated with P bivia or saline solution in a planned ratio of 4:1 (24 P bivia: 6 saline solution). Rabbits were inoculated 6 cm transcervically with 10(5) to 10(8) colony-forming units/uterine horn of P bivia or with saline solution. Necropsy was scheduled on days 4, 6, or 7 after inoculation. Cultures were collected from blood, uterus, amniotic fluid and fetal brain, lung, and heart. Tissues from placenta, uterus, fetal brain, and lung were evaluated with the histologic inflammation score, with a range of 0 to 13. Amniotic fluid was assayed for tumor necrosis factor-alpha by bioassay. Animals with contamination by other organisms were excluded. Categoric data were evaluated with the use of the Fisher exact test, and continuous data were evaluated with the use of the Wilcoxon rank sum. RESULTS After the exclusion of 8 animals because of contamination with other organisms, 22 animals were evaluated. Of 3 rabbits with an inoculum of 10(8) P bivia colony-forming units/horn, 2 animals (67%) had fever within 24 hours. These results were not compatible with chronic, subclinical infection. Therefore, 14 does had inocula of 10(5-6) P bivia colony-forming units/horn, with necropsy planned at day 4 (n=5 animals), day 6 (n=3 animals), and day 7 (n=6 animals), and 5 animals were inoculated with saline solution. Animals that had been inoculated with P bivia were significantly more likely to have a positive culture than were those animals that were inoculated with saline solution (64% vs 0%; P<.04). Preterm delivery without fever occurred in 21% of does (3/14 does) that were inoculated with P bivia overall and in 33% of the does (3/9 does) that were followed for 6 to 7 days. No saline-solution inoculated animal had preterm birth. There was an increase in amniotic fluid tumor necrosis factor-alpha levels over time in the P bivia group (P=.12). Histologic inflammation scores were not significantly different between P bivia and saline solution groups. CONCLUSION Inoculation with P bivia at 10(5-6) colony-forming units/horn leads to chronic intrauterine and fetal infection that are accompanied by preterm birth in up to 33% of cases. This model may serve to explore the mechanism of preterm birth that is induced by chronic infection with genital tract anaerobes.
Collapse
Affiliation(s)
- Ronald S Gibbs
- Department of Obstetrics and Gynecology, University of Colorado Health Sciences Center, Denver, 80262, USA
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Mingo-Sion AM, Marietta PM, Koller E, Wolf DM, Van Den Berg CL. Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells. Oncogene 2004; 23:596-604. [PMID: 14724588 DOI: 10.1038/sj.onc.1207147] [Citation(s) in RCA: 131] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
c-Jun N-terminal kinase (JNK) is activated by diverse cell stimuli, including stress, growth factors, and cytokines. Traditionally, activation of JNK by stress treatment is thought to induce cell death. However, our recent data indicate that JNK's ability to sensitize cells to apoptosis may be, in part, cell cycle dependent. Here, we show that the majority of both paclitaxel- and UV-induced apoptosis can be inhibited by the pharmacological JNK inhibitor, SP600125, in MCF-7 cells. However, inhibition of JNK does little to reverse doxorubicin-induced apoptosis in MCF-7 cells or doxorubicin- and UV-mediated death in MDA MB-231 cells. SP treatment causes G2/M arrest of three breast cancer cell lines and results in the endoreduplication (cellular DNA content >4N) of MCF-7 and MDA MB-231 cells. These effects on cell cycle and apoptosis are not significantly altered by the inhibition of p53, indicating that JNK is functioning independently of p53. Lastly, inhibition of JNK using both SP and antisense oligonucleotides targeted to JNK1 and JNK2 reduced proliferation of all three breast cancer cell lines. Taken together, these results suggest that the activation of JNK is important for the induction of apoptosis following stresses that function at different cell cycle phases, and that basal JNK activity is necessary to promote proliferation and maintain diploidy in breast cancer cells.
Collapse
Affiliation(s)
- Amy M Mingo-Sion
- School of Pharmacy, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Campus Box C238, Denver, CO 80262, USA
| | | | | | | | | |
Collapse
|
14
|
Abstract
OBJECTIVE To identify risk factors that place a term nulliparous patient in labor at risk for cesarean delivery. METHODS This was a case-control, chart review study of 325 nulliparous patients presenting in labor at term with singleton vertex fetuses with either cesarean (patients) or vaginal (controls) delivery. Dichotomous variables were analyzed by chi(2) or Fisher exact tests; continuous variables were assessed by the Wilcoxon two-sample test. Multiple logistic regression was used to identify independent risk factors for cesarean delivery, and a model for predicting risk was built and evaluated. RESULTS In univariate analysis, 22 variables were significantly different between patients and controls. Of 11 that were known within 2 hours of admission, five (change in cervical dilatation, maternal weight, gestational age, fetal station at 2 hours, and preeclampsia) remained independently significant in a multiple logistic regression model for cesarean delivery. The multiple regression model could divide our study population into quintiles in which the lowest risk group had a 5% incidence and the highest risk group had an 88% incidence of cesarean delivery. CONCLUSION It may be possible to offer early cesarean delivery to patients at highest risk, reducing the potential morbidity of long labor or failed operative vaginal delivery followed by a later cesarean delivery.
Collapse
Affiliation(s)
- Paul T Wilkes
- University of Colorado Health Sciences Center, Department of Obstetrics and Gynecology, Denver, Colorado 80262, USA
| | | | | | | | | |
Collapse
|
15
|
Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 2002; 277:5209-18. [PMID: 11717311 DOI: 10.1074/jbc.m110090200] [Citation(s) in RCA: 416] [Impact Index Per Article: 18.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The PR-A and PR-B isoforms of progesterone receptors (PR) have different physiological functions, and their ratio varies widely in breast cancers. To determine whether the two PR regulate different genes, we used human breast cancer cell lines engineered to express one or the other isoform. Cells were treated with progesterone in triplicate, time-separated experiments, allowing statistical analyses of microarray gene expression data. Of 94 progesterone-regulated genes, 65 are uniquely regulated by PR-B, 4 uniquely by PR-A, and only 25 by both. Almost half the genes encode proteins that are membrane-bound or involved in membrane-initiated signaling. We also find an important set of progesterone-regulated genes involved in mammary gland development and/or implicated in breast cancer. This first, large scale study of PR gene regulation has important implications for the measurement of PR in breast cancers and for the many clinical uses of synthetic progestins. It suggests that it is important to distinguish between the two isoforms in breast cancers and that isoform-specific genes can be used to screen for ligands that selectively modulate the activity of PR-A or PR-B. Additionally, use of natural target genes, rather than "consensus" response elements, for transcription studies should improve our understanding of steroid hormone action.
Collapse
Affiliation(s)
- Jennifer K Richer
- Department of Medicine/Endocrinology, University of Colorado School of Medicine, Denver, Colorado 80262, USA.
| | | | | | | | | | | |
Collapse
|
16
|
Gibbs RS, Davies JK, McDuffie RS, Leslie KK, Sherman MP, Centretto CA, Wolf DM. Chronic intrauterine infection and inflammation in the preterm rabbit, despite antibiotic therapy. Am J Obstet Gynecol 2002; 186:234-9. [PMID: 11854641 DOI: 10.1067/mob.2002.119640] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJECTIVE In a pregnant rabbit model using intracervical inoculation of Escherichia coli with delayed antibiotic therapy, we investigated the rate of positive cultures and histologic inflammation of maternal and fetal compartments and the concentration of tumor necrosis factor-alpha in the amniotic fluid for up to 5 days. STUDY DESIGN New Zealand White rabbits at 70% gestation were inoculated intracervically with 10(3) - 10(4) colony-forming units of E coli per uterine horn. At varying intervals after inoculation (0.5 - 4.0 hours), antibiotic therapy was initiated with ampicillin-sulbactam. Primary outcomes were positive cultures and histologic inflammation score. Tumor necrosis factor-alpha levels in the amniotic fluid were determined by bioassay. RESULTS A total of 60 animals were inoculated with E coli. At the endpoint, uterine cultures were positive more commonly than in the fetus or amniotic fluid (41.8% vs 27.5% vs 17.3%, respectively), which was consistent with an ascending pathway of infection. Inflammation scores were similar in uterus and placenta but lower in fetal lung and absent in fetal brain (2.8 vs 3.1 vs 0.84 vs 0.0, respectively). Comparing the durations of delay in antibiotic administration, we found a significant increase in positive uterine cultures and a significant increase in histologic inflammation score with increasing delay. The proportion of dead pups within a litter was significantly associated with the log of the tumor necrosis factor-alpha concentration in amniotic fluid and the degree of histologic inflammation in the uterus, but not with amniotic fluid or other culture positivity. CONCLUSION The administration of therapeutic doses of antibiotic does not consistently eradicate bacteria from the rabbit uterus nor, more importantly, from the fetus and the amniotic fluid. Obtaining a negative amniotic fluid culture does not exclude either infection in the decidua or the fetus or histologic inflammation with tumor necrosis factor-alpha elaboration.
Collapse
Affiliation(s)
- Ronald S Gibbs
- Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Denver, CO, USA
| | | | | | | | | | | | | |
Collapse
|
17
|
Dai D, Wolf DM, Litman ES, White MJ, Leslie KK. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res 2002; 62:881-6. [PMID: 11830547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
Progesterone is a critical steroid hormone that controls cell proliferation and differentiation in the female reproductive tract. Progesterone acts through two nuclear receptor isoforms, progesterone receptors A and B (PRA and PRB, respectively), each with unique cellular effects. Loss of PRB has recently been linked to the development of poorly differentiated endometrial tumors, a lethal form of cancer. To study the molecular effects of progesterone, progesterone receptors were introduced into Hec50co endometrial cancer cells by adenoviral vectors encoding either PRA or PRB. Progesterone induced the cyclin-dependent kinase inhibitors p21 and p27, thereby significantly reducing the percentage of proliferating cells. Cancer cell invasion was also markedly inhibited as measured by Matrigel invasion studies. Similarly, a differentiated, secretory phenotype was induced by progesterone in cells expressing PRB. However, replicative senescence was induced by progesterone only in cells expressing PRA. Expression array analysis followed by confirmatory semiquantitative reverse transcription-PCR experiments demonstrated a significant progesterone-dependent inhibition of expression of a cadre of cellular adhesion molecules, including fibronectin, integrin alpha3, integrin beta1, integrin beta3, and cadherin 6. The level of down-regulation of adhesion molecule expression was significantly greater in the presence of the B isoform, demonstrating that progesterone acts principally through B receptors to inhibit cancer cell invasiveness modulated by adhesion molecules.
Collapse
Affiliation(s)
- Donghai Dai
- The Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, 2211 Lomas Boulevard NE, Albuquerque, New Mexico 87131-5286, USA
| | | | | | | | | |
Collapse
|
18
|
Xing EP, Wolf DM, Dubchak I, Spengler S, Zorn M, Muchnik I, Kulikowski C. Automatic discovery of sub-molecular sequence domains in multi-aligned sequences: a dynamic programming algorithm for multiple alignment segmentation. J Theor Biol 2001; 212:129-39. [PMID: 11531380 DOI: 10.1006/jtbi.2001.2319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Automatic identification of sub-structures in multi-aligned sequences is of great importance for effective and objective structural/functional domain annotation, phylogenetic treeing and other molecular analyses. We present a segmentation algorithm that optimally partitions a given multi-alignment into a set of potentially biologically significant blocks, or segments. This algorithm applies dynamic programming and progressive optimization to the statistical profile of a multi-alignment in order to optimally demarcate relatively homogenous sub-regions. Using this algorithm, a large multi-alignment of eukaryotic 16S rRNA was analyzed. Three types of sequence patterns were identified automatically and efficiently: shared conserved domain; shared variable motif; and rare signature sequence. Results were consistent with the patterns identified through independent phylogenetic and structural approaches. This algorithm facilitates the automation of sequence-based molecular structural and evolutionary analyses through statistical modeling and high performance computation.
Collapse
Affiliation(s)
- E P Xing
- Center for Bioinformatics and Computational Genomics, NERSC, Berkeley, CA 94720, USA
| | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
OBJECTIVE Endometrial cancers often arise in a setting of estrogen stimulation unopposed by the differentiating effects of progesterone. Our laboratory and others have previously shown that progesterone receptor down-regulation or perturbation of progesterone receptor isoform A or B expression is associated with the development of poorly differentiated endometrial cancers that are not growth inhibited by progestins. The purpose of these studies was to reestablish high progesterone receptor isoform A and B gene expressions in such endometrial cancer cells and to examine the effects of progestin treatment on cell growth and metastatic potential after this transformation. STUDY DESIGN To induce high levels of expression of the progesterone receptor isoforms in KLE and Hec50 endometrial cancer cells, adenoviral vectors encoding the genes for progesterone receptor isoforms A and B were created. The characteristic ability of cancer cells to grow independently of anchorage to the surrounding solid matrix was measured by counting colony formation on soft agar for 8 to 14 days. Cell proliferation in response to a time course of progestin treatment was tested with flow cytometry. RESULTS After treatment with a control vector without a progesterone receptor--encoding insert, no effect of progestin treatment on cell proliferation was found; after treatment with vectors encoding progesterone receptor isoform A or B, however, progestin treatment resulted in significant inhibition of cell growth. The anchorage-independent cell growth on soft agar assay showed that by 8 to 14 days the number of cell colonies was reduced by 50% relative to control preparations in the presence of progesterone receptor isoform A plus progestin (P <.0001, both Hec50 and KLE cell lines) and by 90% in the presence of progesterone receptor isoform B plus progestin (P <.0001, both Hec50 and KLE cell lines). Progestin treatment also resulted in a time-dependent reduction in cell proliferation as measured by flow cytometry. Although transfection with both progesterone receptor isoforms A and B reduced cell proliferation according to our assays, progesterone receptor isoform B caused a much more dramatic decrease in cell growth (P =.001, Hec50 cells; P <.0001, KLE cells). CONCLUSION In poorly differentiated endometrial cancer cells that are resistant to progestin therapy, adenovirus-induced expressions of progesterone receptors A and B reestablish progestin control of endometrial cancer cell proliferation.
Collapse
Affiliation(s)
- D Dai
- Division of Basic Reproductive Science, Department of Obstetrics and Gynecology, The University of Colorado Health Sciences Center, Denver, USA
| | | | | | | |
Collapse
|
20
|
Xing P, Kulikowski C, Muchnik I, Dubchak I, Wolf DM, Spengler S, Zorn M. Analysis of ribosomal RNA sequences by combinatorial clustering. Proc Int Conf Intell Syst Mol Biol 2000:287-96. [PMID: 10786312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
We present an analysis of multi-aligned eukaryotic and procaryotic small subunit rRNA sequences using a novel segmentation and clustering procedure capable of extracting subsets of sequences that share common sequence features. This procedure consists of: i) segmentation of aligned sequences using a dynamic programming procedure, and subsequent identification of likely conserved segments; ii) for each putative conserved segment, extraction of a locall homogeneous cluster using a novel polynomial procedure; and iii) intersection of clusters associated with each conserved segment. Aside from their utilit in processing large gap-filled multi-alignments, these algorithms can be applied to a broad spectrum of rRNA analysis functions such as subalignment, phylogenetic subtree extraction and construction, and organism tree-placement, and can serve as a framework to organize sequence data in an efficient and easily searchable manner. The sequence classification we obtained using the method presented here shows a remarkable consistency with the independently constructed eukaryotic phylogenetic tree.
Collapse
Affiliation(s)
- P Xing
- DIMACS and CS Department, Rutgers University, Piscataway, NJ 08855-1179, USA.
| | | | | | | | | | | | | |
Collapse
|
21
|
Bhatia N, Zhao J, Wolf DM, Agarwal R. Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin. Cancer Lett 1999; 147:77-84. [PMID: 10660092 DOI: 10.1016/s0304-3835(99)00276-1] [Citation(s) in RCA: 98] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Several studies from our laboratory have shown the cancer chemopreventive and anti-carcinogenic effects of silymarin, a flavonoid antioxidant isolated from milk thistle, in long-term tumorigenesis models and in human prostate, breast and cervical carcinoma cells. Since silymarin is composed mainly of silibinin with small amounts of other stereoisomers of silibinin, in the present communication, studies were performed to assess whether the cancer preventive and anti-carcinogenic effects of silymarin are due to its major component silibinin. Treatment of different prostate, breast, and cervical human carcinoma cells with silibinin resulted in a highly significant inhibition of both cell growth and DNA synthesis in a time-dependent manner with large loss of cell viability only in case of cervical carcinoma cells. When compared with silymarin, these effects of silibinin were consistent and comparable in terms of cell growth and DNA synthesis inhibition, and loss of cell viability. Based on the comparable results of silibinin and silymarin, we suggest that the cancer chemopreventive and anti-carcinogenic effects of silymarin reported earlier are due to the main constituent silibinin.
Collapse
Affiliation(s)
- N Bhatia
- Center for Cancer Causation and Prevention, AMC Cancer Research Center, Denver, CO 80214, USA
| | | | | | | |
Collapse
|
22
|
Abstract
In this project we study the relationship between genomic regulatory element organization and gene regulatory dynamics. This paper illustrates an approach to investigating this relationship based on the application of classical nonlinear system analysis techniques to a transcription level, statistical thermodynamical model like that used in Shea & Ackers (1985). Preliminary ideas presented at the ICMCM conference (Wolf & Eeckman, 1998) are developed in this manuscript. We show that, for prokaryotic gene circuits dominated by local promoter control, dynamical system behavior descriptors like the number and stability of equilibrium point steady states and their bifurcation potential can be largely determined from genomic organization (e.g. the number, type, and placement of regulatory protein binding sites). Concepts are illustrated on hypothetical gene regulation systems with one or two genes and varying numbers of regulatory protein binding sites (operators). Gene regulatory systems with a single gene and an arbitrary number of operator sites are shown to be globally stable, with the potential for having multiple equilibrium points and capable of bifurcating. A monomer-controlled gene regulation system with n operator sites is proven to have a maximum of 1+n/2 stable equilibria for even n, and (n+1)/2 for odd n, while a multimer-controlled, n operator site system is shown to have a maximum of 2+n/2 stable equilibria for even n, and (n+3)/2 for odd n. These results are applied to the design of a two-state switch using a gene regulation system with two operator sites. The question "what is the simplest possible gene regulation system capable of acting like a switch?" is answered. The paper ends with an analysis of a two-gene regulation system, the results of which point to the existence of a "soft-switching" mechanism that may account for the "on-off" hypothesized behavior of some gene networks.
Collapse
Affiliation(s)
- D M Wolf
- NERSC Bioinformatics Group, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, CA 94720, USA.
| | | |
Collapse
|
23
|
Abstract
Reinfusion of residual tumor cells into B cell non-Hodgkin's lymphoma (B-NHL) patients during autologous transplantation may be an important cause of disease relapse. Determining the extent to which B-NHL cells are present in autologous progenitor cell products and if the presence of residual B-NHL cells is predictive of relapse will require extremely sensitive methods of detecting rare B-NHL cells. We attempted to improve the sensitivity of polymerase chain reaction (PCR)-based detection of rare B-NHL cells by preselecting CD19+ cells using an immunomagnetic column. To measure detection sensitivity, we prepared samples containing different levels of B-NHL cell contamination by mixing B-NHL cell lines containing the chromosomal translocation t(14;18) bcl-2/JH) with control leukapheresis samples. DNA extracted from each CD19-selected sample and from each matched nonselected sample was added to a PCR to amplify the bcl-2/JH breakdown junction. CD19 preselection improved the sensitivity of detection of t(14;18)-positive B-NHL cells 115-fold, so that B-NHL cells at a concentration of 1 tumor cell per 1 x 10(6) hematopoietic cells were detected in every specimen evaluated. t(14;18)-positive cells were not detected in any of 13 control leukapheresis specimens. We conclude that a combination of CD19 preselection and PCR amplification may improve the sensitivity of detection of rare lymphoma cells by two orders of magnitude without a significant decrease in specificity.
Collapse
Affiliation(s)
- R E Pugh
- Department of Pathology, University of Colorado Health Sciences Center, Denver 80262, USA
| | | | | | | | | | | |
Collapse
|
24
|
Lee AV, Weng CN, McGuire SE, Wolf DM, Yee D. Lac repressor inducible gene expression in human breast cancer cells in vitro and in a xenograft tumor. Biotechniques 1997; 23:1062-8. [PMID: 9421637 DOI: 10.2144/97236st02] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
We have studied the lac repressor (lacR) system in two breast cancer cell lines, MCF-7 and MDA-MB-231, in vitro and in vivo. Breast cancer cell lines were stably transfected with lacR and tested for inducibility by transient transfection with a lac operator/luciferase reporter plasmid. The level of expression of lacR did not appear to correlate with the basal or maximal activation of induction by isopropyl beta-D-thiogalactoside (IPTG). Stable transfection with the same reporter gene resulted in up to 40-fold (MDA-MB-231) and 50-fold (MCF7) induction. In the absence of IPTG, a low level of basal reporter gene expression was seen in all clones. Detailed analysis showed that induction was rapid (maximal at 24 h), reversible (a return to basal expression by 24 h) and dose-dependent. To test if this system was also inducible in vivo, cells were grown as a xenograft tumor in nude mice. Mice were given IPTG (0.53 mmol) by intraperitoneal injection, and the tumors were biopsied at several time points following administration. IPTG caused a 10-fold increase in luciferase activity after 8 h, which persisted for 24 h. Thus, this system allows tightly controlled inducible in vivo and in vitro gene expression with low basal expression, and it may provide an important tool for the study of lethal genes in human breast cancer cells.
Collapse
Affiliation(s)
- A V Lee
- Department of Medicine, University of Texas Health Science Center at San Antonio 78284-7884, USA
| | | | | | | | | |
Collapse
|
25
|
Zhang QX, Borg A, Wolf DM, Oesterreich S, Fuqua SA. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res 1997; 57:1244-9. [PMID: 9102207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Thirty tumors from metastatic breast cancer patients were screened for mutations in the estrogen receptor (ER) gene using single-strand conformation polymorphism and sequence analysis. Three missense mutations, Ser47Thr, Lys531Glu, and Tyr537Asn, were identified in these lesions. To investigate these mutated ERs or altered transcriptional activation function, expression vectors containing wild-type (wt) and mutant ERs were constructed and cotransfected with different estrogen response element reporter gene constructs into HeLa cells and MDA-MB-231 human breast cancer cells. The first two ER mutants were similar to wt ER. However, the Tyr537Asn ER mutant possessed a potent, estradiol-independent transcriptional activity, as compared to wt ER. Moreover, the constitutive activity of the Tyr537Asn ER mutant was virtually unaffected by estradiol, tamoxifen, or the pure antiestrogen ICI 164,384. Tyr537 is located at the beginning of exon 8 in the COOH-terminal portion of the hormone-binding domain of the ER, to which dimerization and transcription activation functions have also been ascribed. It has been identified as a phosphorylation site implicated in hormone binding, dimerization, and hormone-dependent transcriptional activity. Our results suggest that the Tyr537Asn substitution induces conformational changes in the ER that might mimic hormone binding, not affecting the ability of the receptor to dimerize, but conferring a constitutive transactivation function to the receptor. If present in other metastatic breast tumors, this naturally occurring ER mutant may contribute to breast cancer progression and/or hormone resistance.
Collapse
Affiliation(s)
- Q X Zhang
- Department of Oncology, University Hospital, Lund, Sweden
| | | | | | | | | |
Collapse
|
26
|
Bilimoria MM, Assikis VJ, Muenzner HD, Wolf DM, Satyaswaroop PG, Jordan VC. An analysis of tamoxifen-stimulated human carcinomas for mutations in the AF-2 region of the estrogen receptor. J Steroid Biochem Mol Biol 1996; 58:479-88. [PMID: 8918973 DOI: 10.1016/0960-0760(96)00078-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The estrogen receptor (ER) contains two transcriptional activation domains: AF-1 and AF-2. AF-2 is dependent on a highly species-conserved region of the ER. It has been shown that site-directed point mutations of conserved hydrophobic amino acids within this region reduce estrogen-dependent transcriptional activation. In addition, when these mutated ERs are transfected into HeLa cells, both tamoxifen and ICI 164,384 become strong agonists. The implication is that mutations in this region could account for the tamoxifen-stimulated tumors seen clinically. We performed single stranded conformational polymorphism (SSCP) analysis spanning the entire ER along with DNA sequencing of the AF-2 region of the ER isolated from two different tamoxifen-stimulated breast cancers, MCF-7/TAM and MCF-7/MT2, and a tamoxifen-stimulated endometrial cancer, EnCa 101. In addition, a tamoxifen-stimulated endometrial carcinoma cell line, the Ishikawa cell line, was also studied. There were no mutations found by SSCP analysis and sequencing of all four AF-2 regions also revealed no mutations. Mutations within the AF-2 region of the human ER do not appear to account for the growth of human breast and endometrial carcinomas that are used as reproducible laboratory models of tamoxifen-stimulated growth observed clinically.
Collapse
Affiliation(s)
- M M Bilimoria
- Department of Surgery, Northwestern University Medical School, Chicago, IL 60611, U.S.A
| | | | | | | | | | | |
Collapse
|
27
|
Abstract
Alterations in the amino acid sequence of the estrogen receptor (ER) have been shown to have dramatic effects on its function. Recently, mutant ERs have been isolated from both clinical samples and established breast cancer cell lines, primarily through the use of the polymerase chain reaction (PCR). All previously reported mutations have given rise to either alterations or truncations of the ER protein. We determined the structure of a novel 80 kDa ER which is expressed in an estrogen independent subclone of the MCF-7 human breast cancer cell line (MCF-7:2A). This 80 kDa ER was initially detected by Western blot analysis using a variety of ER specific antibodies. PCR mapping and partial PCR mediated subcloning of the ER cDNA were used to demonstrate that this protein was an ER containing an in-frame duplication of exons 6 and 7. This type of duplication has not been previously described for any members of the steroid receptor superfamily. Karyotype analysis coupled with fluorescence in situ hybridization (FISH) demonstrated that MCF-7:2A cells contained 4-5 copies of the ER gene in contrast to 2 copies in MCF-7:WS8 cells. The ER gene was localized by FISH analyses in both the MCF-7:WS8 and MCF-7:2A cells on chromosome 6, which is the source of the ER in normal human cells. The relative expression level of 2:1 is consistent with DNA gene dosage analysis. Genomic PCR was then used to demonstrate that the 80 kDa ER mRNA was not derived from the trans-splicing of two ER mRNAs but was the result of a genomic rearrangement in which exons 6 and 7 were duplicated in an in-frame fashion. This variant ER may prove to be useful in elucidating the mechanism of estrogen action in breast cancer cells.
Collapse
Affiliation(s)
- J J Pink
- Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison 53792, USA
| | | | | | | | | |
Collapse
|
28
|
Abstract
Measurements of the estrogen receptor (ER) and the estrogen-induced progesterone receptor (PgR) are used by most clinicians as indicators of both overall prognosis and likelihood of response to endocrine therapy. Patients with ER+/PgR+ tumors have the highest likelihood of response; conversely, patients with ER-/PgR-tumors have the lowest likelihood of response. Unfortunately, most patients treated successfully with endocrine therapy eventually develop endocrine-resistant disease recurrence. In an effort to study potential mechanisms of endocrine resistance, we have studied discordant ER-/PgR+ tumors, in which the normally estrogen-regulated PgR gene is induced in the apparent absence of ER. Our laboratory has previously cloned, from ER-/PgR+ tumors, a variant ER mRNA precisely missing the sequence corresponding to ER exon 5, and has demonstrated that the truncated protein product translated from this variant RNA is capable of constitutively inducing the expression of an estrogen-responsive reporter gene in a yeast expression vector system (Fuqua et al. Cancer Res 51:105-109, 1991). In the present report we describe further experiments to characterize the activity and biological consequences of expression of this variant ER in human breast cancer cells. We have stably transfected MCF-7 human breast cancer cells with a mammalian expression vector for the exon 5 deletion variant ER. These transfected cells produce a truncated ER protein of the expected 40 kDa size. Cells expressing the exon 5 ER deletion variant constitutively express PgR, and manifest increased anchorage-independent colony formation in the absence of estrogen.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- S A Fuqua
- Department of Medicine, University of Texas Health Science Center at San Antonio 78284-7884, USA
| | | |
Collapse
|
29
|
Abstract
We previously identified a codon 351 (Asp-->Tyr) mutant estrogen receptor (ER) in a tamoxifen-stimulated human breast tumor line. To examine its biological activity, we have constructed cell lines from the ER-negative human breast cancer cell line MDA-MB-231 that stably express either the wild type (S30) or mutant ER (BC-2). ER expression was confirmed by Western blot, ligand-binding studies, and ER-enzyme immunoassay. The growth characteristics of the S30 and BC-2 cell lines were compared when treated with estradiol, fixed-ring 4-hydroxytamoxifen [(fr) 4-OH TAM], or ICI 182,780. (fr) 4-OH TAM is a stable, high affinity tamoxifen analog. Many investigators have recognized that growth of ER-negative cell lines stably transfected with ER is inhibited by estradiol. Similarly, both S30 and BC-2 cell lines are inhibited by estradiol in a concentration-dependent manner. (fr) 4-OH TAM has no effect on S30 proliferation but inhibits the growth of BC-2 cells. The pure antiestrogen ICI 182,780 can block the growth-inhibitory effect of estradiol in both cell lines and the growth-inhibitory effect of (fr) 4-OH TAM in the BC-2 cells. In transient transfection analyses using a luciferase reporter plasmid containing two copies of the Xenopus vitellogenin A2 estrogen response element, estradiol stimulated luciferase transcription through both the wild type and mutant estrogen receptors, while (fr) 4-OH TAM stimulated transcription to a greater extent through the mutant receptor. These results demonstrate that the estrogenicity of (fr) 4-OH TAM is increased by binding to the codon 351 mutant ER, and that ER activation and growth inhibition are associated.
Collapse
Affiliation(s)
- W H Catherino
- Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison 53792, USA
| | | | | |
Collapse
|
30
|
Affiliation(s)
- V C Jordan
- Robert H. Lurie Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611, USA
| | | | | |
Collapse
|
31
|
Abstract
Investigators from laboratories worldwide have spent nearly 40 years studying the mechanisms by which the diverse class of compounds known as antiestrogens exert their effects. In this review we present an overview of the work to date that has led to a greater understanding of both the classical and the sometimes unexpected actions which an antiestrogenic compound can have on the growth of a cell. In addition, we review work which has begun to explain the means by which some cells can ultimately become resistant to the action of antiestrogens. We conclude with a discussion of the current directions being followed by researchers in this area, as well as with several comments regarding what physiological activities might be desired in an 'ideal' antiestrogenic compound.
Collapse
Affiliation(s)
- D M Wolf
- Department of Medicine, University of Texas Health Science Center at San Antonio 78284-7884, USA
| | | |
Collapse
|
32
|
Wolf DM, Jordan VC. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 1994; 31:129-38. [PMID: 7981453 DOI: 10.1007/bf00689683] [Citation(s) in RCA: 120] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The nonsteroidal antiestrogen tamoxifen (TAM) is the most commonly used endocrine treatment for all stages of breast cancer in both pre- and postmenopausal women. However, the development of resistance to the drug is common, as most patients treated with TAM eventually experience a recurrence of tumor growth. One of the potential mechanisms of treatment failure is the acquisition by the tumor of the ability to respond to TAM as a stimulatory rather than inhibitory ligand. We (Gottardis and Jordan, Cancer Res 48:5183-5187, 1988; Wolf et al., J Natl Cancer Inst 85:806-812, 1993) and others (Osborne et al., Eur J Cancer Clin Oncol 23: 1189-1196, 1987; Osborne et al., J Natl Cancer Inst 83: 1477-1482, 1991) have extensively described the reproducible development of TAM stimulated growth in a laboratory model system using MCF-7 human breast cancer cells grown as solid tumors in athymic mice. In this paper we report on the isolation of an estrogen receptor (ER) from a TAM stimulated tumor (MCF-7/MT2) which contains a point mutation that causes a tyrosine for aspartate substitution at amino acid 351 in the ligand binding domain. The mutant appears to the major form of ER expressed by this tumor. We also report that only wild type ER was detected in three other TAM stimulated MCF-7 tumor variants, suggesting that multiple mechanisms are possible for the development of TAM stimulated growth. The implications of these findings are discussed.
Collapse
Affiliation(s)
- D M Wolf
- Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison 53792
| | | |
Collapse
|
33
|
Abstract
The non-steroidal antiestrogen tamoxifen (TAM) is successfully used to treat all stages of breast cancer in both pre- and postmenopausal women. Unfortunately, most women treated with TAM eventually develop resistant tumor recurrences which require intervention with a second-line endocrine therapy, or cytotoxic chemotherapy if the recurrence is completely endocrine insensitive. There is evidence that some recurrences may in fact be TAM stimulated. MCF-7 human breast cancer cells grown as solid tumors in athymic mice chronically treated with TAM reproducibly develop a TAM stimulated phenotype (Osborne et al., Eur J Cancer Clin Oncol 23:1189-1196, 1987; Gottardis and Jordan, Cancer Res 48: 5183-5187, 1988; Osborne et al., J Natl Cancer Inst 83:1477-1482, 1991; Wolf et al., J Natl Cancer Inst 85:806-812, 1993). Tumors of this type may provide a useful model for a subset of therapeutic failures in the clinic. Therefore, we have extensively studied this model in an attempt to define the mechanism or mechanisms leading to TAM stimulated growth. In this paper we describe the characteristics of 4 TAM stimulated MCF-7 tumor variants. All of these tumors are growth stimulated by TAM, but vary in their response to estradiol (E2) treatment, and grow poorly in placebo treated hosts. All tumor variants express estrogen receptor (ER) RNA and protein, which at the RNA level appear to be down regulated by TAM, and to a greater extent by E2. All tumors also express epidermal growth factor receptor (EGFR) RNA, which is down regulated by TAM, and further down regulated by E2. However, among the tumor variants analyzed, ER and EGFR levels appear to be inversely related. Further, despite the expression of ER by all 4 TAM stimulated tumor variants, E2 induction of progesterone receptor expression is very weak or entirely absent.
Collapse
MESH Headings
- Animals
- Blotting, Western
- Breast Neoplasms/pathology
- Cell Division/drug effects
- Cell Line
- Clone Cells
- Female
- Genetic Variation
- Humans
- Mice
- Mice, Nude
- Postmenopause
- Premenopause
- RNA, Messenger/isolation & purification
- RNA, Messenger/metabolism
- RNA, Neoplasm/isolation & purification
- RNA, Neoplasm/metabolism
- Receptors, Estrogen/analysis
- Receptors, Progesterone/analysis
- Tamoxifen/pharmacology
- Time Factors
- Transplantation, Heterologous
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- D M Wolf
- Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison 53792
| | | |
Collapse
|
34
|
Wolf DM, Powers JM, O'Keefe KL. Bond strength of composite to etched and sandblasted porcelain. Am J Dent 1993; 6:155-8. [PMID: 8240779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
In vitro tensile bond strengths of composite to porcelain treated by acid etching or sandblasting were measured. A 9.5% HF gel was applied for 30, 60, 150, or 300 seconds at 23 degrees C. Al2O3 particles were applied as wet-10.2, dry-33.5, dry-48.0, or dry-78.0 microns. Average roughness (Ra) was measured by profilometry before and after each treatment. Both longer etching time and sandblasting using Al2O3 with larger particle sizes produced increased surface roughness of porcelain. Etching with 9.5% hydrofluoric acid gel produced higher bond strengths than sandblasting with a series of Al2O3 particles. Etching longer than 60 seconds produced increased cohesive failures in porcelain, whereas most failures observed with sandblasted surfaces were adhesive.
Collapse
Affiliation(s)
- D M Wolf
- Oral Biomaterials, UTHHSC, Dental Branch Houston, TX 77225
| | | | | |
Collapse
|
35
|
Wolf DM, Langan-Fahey SM, Parker CJ, McCague R, Jordan VC. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J Natl Cancer Inst 1993; 85:806-12. [PMID: 8487325 DOI: 10.1093/jnci/85.10.806] [Citation(s) in RCA: 74] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
BACKGROUND The nonsteroidal anti-estrogen tamoxifen (TAM) is the front-line endocrine treatment for breast cancer, but disease recurrence is common. Treatment failure may occur because tumors become insensitive to TAM. Alternatively, resistance may occur because tumors become stimulated rather than inhibited by TAM. TAM-stimulated growth of MCF-7 human breast tumors has been observed in athymic mice after prolonged treatment with TAM. PURPOSE Our purpose was to examine the mechanism of treatment failure by determining whether TAM-stimulated tumors acquire the ability to excrete TAM and its anti-estrogenic metabolites or to convert them to estrogenic compounds with weakened antiestrogenic activity. METHODS We used high-pressure liquid chromatography to quantitate TAM and its metabolites in serum and tumors from ovariectomized athymic mice and in MCF-7 cells grown in vitro. We treated tumor-bearing mice with subcutaneous sustained-release preparations of estradiol, TAM, or a nonisomerizable (fixed-ring) analogue and then assessed the activity of these compounds on TAM-inhibited parental MCF-7 tumors and on TAM-stimulated MCF-7 TAM tumors. RESULTS We found negligible differences in intratumoral TAM levels between TAM-inhibited parental MCF-7 tumors and TAM-stimulated MCF-7 TAM variants. We did not detect metabolite E (Met E), an estrogenic TAM metabolite, in serum or tumors. Using MCF-7 cells in vitro, we determined that the (Z) isomer of Met E, the form directly produced by TAM metabolism, must be present in the cell at a concentration of over 1000 ng/g to overcome growth inhibition by physiological levels of TAM and antiestrogenic metabolites, but the (E) isomer of Met E was effective at 10 ng/g. We reasoned that conversion of Met E from the (Z) (a weak estrogen) to (E) isomer (a potent estrogen) would be required if formation of Met E were responsible for TAM-stimulated growth. However, fixed-ring TAM, which can only form (Z) Met E, was shown to be as capable as TAM of initiating and maintaining anti-estrogen-stimulated growth of MCF-7 tumors in athymic mice. CONCLUSION Metabolism and isomerization of TAM to estrogenic compounds is not the mechanism of TAM-stimulated growth in our model. IMPLICATION Other potential mechanisms for TAM-stimulated growth, such as estrogen receptor mutation, must be investigated so that effective strategies can be devised to control breast cancer once therapy fails.
Collapse
Affiliation(s)
- D M Wolf
- Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison 53792
| | | | | | | | | |
Collapse
|
36
|
Affiliation(s)
- D M Wolf
- Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison 53792
| | | |
Collapse
|
37
|
Abstract
Breast cancer is the most common malignancy occurring in Western women, and is one of the leading causes of cancer mortality. The nonsteroidal antiestrogen tamoxifen has been shown to be an effective treatment for pre and postmenopausal women with all stages of the disease. Tamoxifen provides effective palliation when used to treat patients with advanced disease, and adjuvant tamoxifen therapy produces significant increases in both disease-free and overall survival (Early Breast Cancer Trialists Collaborative Group. Lancet 339:1-15, 71-85, 1992). Data from the laboratory have shown that the primary action of tamoxifen is tumoristatic rather than tumoricidal, and long-term therapy is therefore recommended. Unfortunately, many patients experience disease progression while taking tamoxifen. Some tamoxifen resistant tumors may remain sensitive to alternative endocrine therapies, while others may become refractory to any hormonal manipulation. Many models have been developed in vitro and in vivo to study the progression of breast cancer growth from tamoxifen sensitive to tamoxifen resistant. We and others have used long-term estrogen deprivation and long-term tamoxifen exposure to develop cell lines and tumors capable of growth in the presence of clinically relevant tamoxifen concentrations. Recently our laboratory has also shown that mutations in the estrogen receptor can cause an antiestrogen-occupied receptor to behave as though it were occupied by an estrogen. Breast cancer is a highly heterogeneous disease and it is likely that the mechanisms which cause tamoxifen resistant growth are equally heterogeneous. Several of the models from our laboratory and others which may contribute to an understanding of this complex phenomenon are discussed here.
Collapse
Affiliation(s)
- D M Wolf
- Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison 53792
| | | |
Collapse
|
38
|
Abstract
The antiestrogen tamoxifen has been successfully used to control estrogen receptor (ER) and progesterone receptor positive breast cancer. However, the development of antiestrogen resistance is frequently observed in patients following long term treatment. We have studied the development of antiestrogen resistance in vitro and established an antiestrogen resistant variant of MCF-7 cells (clone 5C) after long term culture in estrogen free medium. The growth of clone 5C cells was not altered by either estradiol-17 beta or the antiestrogens 4-hydroxytamoxifen and ICI 164,384. Estrogen-stimulated progesterone receptor and reporter gene expression were markedly reduced in 5C cells compared to wild type MCF-7 cells. Only minor alteration in the levels of ER and no alteration in the affinity of ER for ligand were found in 5C cells. No mutation of ER cDNA in 5C cells was detected by polymerase chain reaction and DNA sequencing. This study demonstrates that change(s) in ER-mediated gene expression rather than the amino acid sequence of the ER itself may be associated with the development of at least one form of antiestrogen resistance.
Collapse
Affiliation(s)
- S Y Jiang
- Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison 53792
| | | | | | | | | |
Collapse
|
39
|
Abstract
In vitro tensile bond strengths of composite to porcelain were evaluated using three pretreatments (HF etching, sandblasting, diamond abrasion) of the porcelain, four bonding agents (Clearfil Porcelain Bond, Porcelain Liner M, Porcelain Liner M with Super-Bond C&B, and Scotchprime) and two storage conditions (24 h and thermocycling). The overall coefficient of variation was 27%. Significant differences among bond strengths were observed, with storage condition being the most important factor, followed by bonding agent and then pretreatment. Thermocycling decreased the bond strength of all samples, but samples treated with Scotchprime were affected least. For 24 h storage, Clearfil Porcelain Bond and Scotchprime had bond strengths above 23 MN/m2 to sandblasted porcelain.
Collapse
Affiliation(s)
- D M Wolf
- University of Texas Health Science Center at Houston, Dental Branch
| | | | | |
Collapse
|
40
|
Abstract
The antiestrogen tamoxifen was originally introduced as a therapy for advanced breast cancer. Today, tamoxifen is used to treat selected patients with all stages of breast cancer, and trials are underway to evaluate its effectiveness as a potential breast cancer preventive. When tamoxifen is used as an adjuvant or preventive, extended patient survival times can be expected, and concerns about iatrogenic complications arising from long-term treatment become important. This review discusses currently available laboratory and clinical data regarding the toxicology of tamoxifen and focuses in particular on the gynecologic complications potentially associated with long-term tamoxifen administration.
Collapse
Affiliation(s)
- D M Wolf
- Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison 53792
| | | |
Collapse
|
41
|
Iino Y, Wolf DM, Langan-Fahey SM, Johnson DA, Ricchio M, Thompson ME, Jordan VC. Reversible control of oestradiol-stimulated growth of MCF-7 tumours by tamoxifen in the athymic mouse. Br J Cancer 1991; 64:1019-24. [PMID: 1764361 PMCID: PMC1977873 DOI: 10.1038/bjc.1991.457] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
We investigated the ability of high concentrations of oestradiol to reverse the growth inhibitory action of tamoxifen on MCF-7 breast cancer cells in vivo. Tamoxifen inhibits the oestradiol stimulated growth of MCF-7 cells in athymic mice. Using a sustained release preparation of tamoxifen we consistently achieved serum concentrations of the drug in the 40 to 50 ng ml-1 range and much higher levels in tissues. These serum levels are sufficient to inhibit the oestrogen stimulated growth of MCF-7 tumours exposed to physiologic (i.e. 300-600 pg ml-1 serum oestradiol concentrations). However, by administering dosages that increase serum oestradiol concentrations to 900-2000 pg ml-1, mimicking the increase often observed clinically in premenopausal women taking tamoxifen, we show that the growth inhibitory action of tamoxifen can be partially reversed. Serum tamoxifen levels were elevated to nearly 400 ng ml-1 by injecting 1 mg day-1 tamoxifen (IP 3 x weekly); this dosage was more effective at inhibiting oestradiol stimulated tumour growth than subcutaneous tamoxifen capsules alone. Our data suggest that at low serum levels tamoxifen may not act optimally. There may be a need to monitor tamoxifen levels in premenopausal patients to ensure that they are high enough not to be overcome by a tamoxifen induced increase in ovarian steroidogenesis.
Collapse
Affiliation(s)
- Y Iino
- Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison 53792
| | | | | | | | | | | | | |
Collapse
|
42
|
Abstract
The authors present an overview of the current status of hysterosalpingography, discussing the advantages and disadvantages of various cannulas, contrast media, and methods of contrast medium introduction. Thirty-two figures illustrate a variety of abnormal findings including among others: intravasation of contrast medium, salpingitis isthmica nodosa, manifestations of pelvic inflammatory disease, the effects of DES exposure, Ascherman's syndrome, adenomyosis, carcinoma, polyps, myomata and developmental uterine abnormalities.
Collapse
Affiliation(s)
- D M Wolf
- Department of Radiology, Strong Memorial Hospital, Rochester, New York 14642
| | | |
Collapse
|